Open Access
Volume 8, Number 1, March 2018
Article Number 1
Number of page(s) 11
Published online 26 February 2018
  1. La Grutta L, Toia P, Maffei E, Cademartiri F, Lagalla R, Midiri M. Infarct characterization using CT. Cardiovasc Diagn Ther. 2017; 7: 171-88. [CrossRef] [Google Scholar]
  2. Rybicki FJ, Piazzo K, Prior R, Wake N, Dill KE. Iodinated contrast injection data from a new technology. Radiol Technol. 2012; 84: 120-5. [PubMed] [Google Scholar]
  3. Meunier B, Joskin J, Damas F, Meunier P. Iodinated contrast media and iodine allergy: myth or reality? Rev Med Liege. 2013; 68: 465-9. [PubMed] [Google Scholar]
  4. Goodwill PW, Saritas EU, Croft LR, Kim TN, Krishnan KM, Schaffer DV, et al. X-space MPI: magnetic nanoparticles for safe medical imaging. Adv Mater. 2012; 24: 3870-7. [CrossRef] [PubMed] [Google Scholar]
  5. Harbron RW, Ainsbury EA, Bouffler SD, Tanner RJ, Eakins JS, Pearce MS. Enhanced radiation dose and DNA damage associated with iodinated contrast media in diagnostic x-ray imaging. Br J Radiol. 201720170028. [Google Scholar]
  6. Mamoulakis C, Tsarouhas K, Fragkiadoulaki I, Heretis I, Wilks MF, Spandidos DA, et al. Contrast-induced nephropathy: Basic concepts, pathophysiological implications and prevention strategies. Pharmacol Ther. 2017. [Google Scholar]
  7. Prezzi D, Khan A, Goh V. Perfusion CT imaging of treatment response in oncology. Eur J Radiol. 2015; 84: 2380-5. [CrossRef] [PubMed] [Google Scholar]
  8. Price DB, Ortiz AO. Myelography: From Lipid-Based to Gadolinium-Based Contrast Agents. Magn Reson Imaging Clin N Am. 2017; 25: 713-24. [CrossRef] [PubMed] [Google Scholar]
  9. Cheng KT. Lipiodol-loaded poly(oxyethylene)-block-poly(oxypropylene)-block-poly(oxyethylene) triblock copolymers/ polyethylene glycol-nanoparticles. In. Molecular Imaging and Contrast Agent Database (MICAD). ed. Bethesda (MD): 2004. [Google Scholar]
  10. Cheng KT. Ioxilan carbonate particles. In. Molecular Imaging and Contrast Agent Database (MICAD). ed. Bethesda (MD): 2004. [Google Scholar]
  11. Lee SY, Rhee CM, Leung AM, Braverman LE, Brent GA, Pearce EN. A review: Radiographic iodinated contrast media-induced thy-roid dysfunction. J Clin Endocrinol Metab. 2015; 100: 376-83. [CrossRef] [PubMed] [Google Scholar]
  12. Costa N. Understanding contrast media. J Infus Nurs. 2004; 27: 302-12. [CrossRef] [PubMed] [Google Scholar]
  13. Bettmann MA, Morris TW. Recent advances in contrast agents. Radiol Clin North Am. 1986; 24: 347-57. [PubMed] [Google Scholar]
  14. Spampinato MV, Abid A, Matheus MG. Current Radiographic Iodinated Contrast Agents. Magn Reson Imaging Clin N Am. 2017; 25: 697-704. [CrossRef] [PubMed] [Google Scholar]
  15. Schrader R. Contrast material-induced renal failure: an overview. J Interv Cardiol. 2005; 18: 417-23. [CrossRef] [PubMed] [Google Scholar]
  16. Pugh ND, Griffith TM, Karlsson JO. Effects of iodinated contrast media on peripheral blood flow. Acta Radiol Suppl. 1995; 399: 155-63. [CrossRef] [PubMed] [Google Scholar]
  17. Stolberg HO, McClennan BL. Ionic versus nonionic contrast use. Curr Probl Diagn Radiol. 1991; 20: 47-88. [CrossRef] [PubMed] [Google Scholar]
  18. ten Dam MA, Wetzels JF. Toxicity of contrast media: an update. Neth J Med. 2008; 66: 416-22. [PubMed] [Google Scholar]
  19. Campbell KL, Hud LM, Adams S, Andrel J, Ballas SK, Feldman AM, et al. Safety of iodinated intravenous contrast medium administration in sickle cell disease. Am J Med. 2012; 125: 100 e11-6. [CrossRef] [Google Scholar]
  20. Katzberg RW, Barrett BJ. Risk of iodinated contrast material-induced nephropathy with intravenous administration. Radiology. 2007; 243: 622-8. [CrossRef] [PubMed] [Google Scholar]
  21. Runge VM. A review of contrast media research in 1999-2000. Invest Radiol. 2001; 36: 123-30. [CrossRef] [PubMed] [Google Scholar]
  22. McCullough PA. Renal safety of iodixanol. Expert Rev Cardiovasc Ther. 2006; 4: 655-61. [CrossRef] [PubMed] [Google Scholar]
  23. Mruk B. Renal Safety of Iodinated Contrast Media Depending on Their Osmolarity - Current Outlooks. Pol J Radiol. 2016; 81: 157-65. [CrossRef] [PubMed] [Google Scholar]
  24. Dawson P. The non-ionic isotonic contrast agents. Perspectives and controversies. Eur Radiol. 1996; 6 Suppl 2: S20-4. [CrossRef] [Google Scholar]
  25. Konen E, Apter S, Morag B, Itzchak Y. Iodinated contrast media: adverse reactions, prevention and treatment. Harefuah. 1995; 128: 719-23. [PubMed] [Google Scholar]
  26. Singh J, Daftary A. Iodinated contrast media and their adverse reactions. J Nucl Med Technol. 2008; 36: 69-74; quiz 76-7. [CrossRef] [PubMed] [Google Scholar]
  27. Weisbord SD, Palevsky PM. Iodinated contrast media and the role of renal replacement therapy. Adv Chronic Kidney Dis. 2011; 18: 199-206. [CrossRef] [PubMed] [Google Scholar]
  28. Weisbord SD. Iodinated contrast media and the kidney. Rev Cardiovasc Med. 2008; 9 Suppl 1: S14-23. [CrossRef] [Google Scholar]
  29. Pintassilgo Santos A, Mascarenhas Gaivao A, Tavares A, Ferreira S. Iodinated contrast agents. Acta Med Port. 2009; 22: 261-74. [PubMed] [Google Scholar]
  30. Erley C. Iodinated contrast agent-induced nephropathy. Radiologe. 2007; 47: 761-7. [CrossRef] [PubMed] [Google Scholar]
  31. Published 2017. Updated Accessed. [Google Scholar]
  32. Hu XH, Gong XY, Hu P. Transient small bowel angioedema due to intravenous iodinated contrast media. World J Gastroenterol. 2012; 18: 999-1002. [CrossRef] [PubMed] [Google Scholar]
  33. 2017 RSROC Contrast Media Manual ( Published 2017. Updated Accessed. [Google Scholar]
  34. Thomsen HS, Morcos SK. Radiographic contrast media. BJU Int 2000; 86 Suppl 1:1-10. [CrossRef] [Google Scholar]
  35. Almen T. The etiology of contrast medium reactions. Invest Radiol. 1994; 29 Suppl 1: S37-45. [CrossRef] [PubMed] [Google Scholar]
  36. Beckett K.R, MAK, Langer J.M. Safe Use of Contrast Media: What the Radiologist Needs to Know. Radiographics. 2015; 35: 1738-50. [CrossRef] [PubMed] [Google Scholar]
  37. Modi K, Dulebohn SC. Contrast Induced Nephropathy. In. Stat-Pearls. ed. Treasure Island (FL): 2017. [Google Scholar]
  38. Ursta AA, Kharkov EI, Petrova MM, Ursta OV, Kotikov AR, Kiselev AN. Contrast induced nephropathy in the older age group patients. Adv Gerontol. 2017; 30: 306-10. [PubMed] [Google Scholar]
  39. Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vas-cular surgery. Br J Anaesth 2016; 117 Suppl 2: ii63-ii73. [CrossRef] [PubMed] [Google Scholar]
  40. Davenport MS, Cohan RH, Ellis JH. Contrast media controversies in 2015: imaging patients with renal impairment or risk of contrast reaction. AJR Am J Roentgenol. 2015; 204: 1174-81. [CrossRef] [PubMed] [Google Scholar]
  41. Homma K. Contrast-induced Acute Kidney Injury. Keio J Med. 2016; 65: 67-73. [CrossRef] [PubMed] [Google Scholar]
  42. McCullough PA, Choi JP, Feghali GA, Schussler JM, Stoler RM, Vallabahn RC, et al. Contrast-Induced Acute Kidney Injury. J Am Coll Cardiol. 2016; 68: 1465-73. [CrossRef] [PubMed] [Google Scholar]
  43. Genovesi E, Romanello M, De Caterina R. Contrast-induced acute kidney injury in cardiology. G Ital Cardiol (Rome) 2016; 17: 984- 1000. [PubMed] [Google Scholar]
  44. Ozkok S, Ozkok A. Contrast-induced acute kidney injury: A review of practical points. World J Nephrol. 2017; 6: 86-99. [CrossRef] [PubMed] [Google Scholar]
  45. Chalikias G, Drosos I, Tziakas DN. Contrast-Induced Acute Kidney Injury: An Update. Cardiovasc Drugs Ther. 2016; 30: 215-28. [CrossRef] [PubMed] [Google Scholar]
  46. Mohammed NM, Mahfouz A, Achkar K, Rafie IM, Hajar R. Contrast-induced Nephropathy. Heart Views. 2013; 14: 106-16. [CrossRef] [PubMed] [Google Scholar]
  47. Wichmann JL, Katzberg RW, Litwin SE, Zwerner PL, De Cecco CN, Vogl TJ, et al. Contrast-Induced Nephropathy. Circulation. 2015; 132: 1931-6. [CrossRef] [PubMed] [Google Scholar]
  48. Contrast-Induced Nephropathy (CIN): Current State of the Evidence on Contrast Media and Prevention of CIN. In. Comparative Effectiveness Review Summary Guides for Clinicians. ed. Rockville (MD): 2007. [Google Scholar]
  49. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Contrast-Induced Nephropathy: An “All or None” Phenomenon? Angiology. 2015; 66: 508-13. [CrossRef] [PubMed] [Google Scholar]
  50. Lameire NH. Contrast-induced nephropathy--prevention and risk reduction. Nephrol Dial Transplant. 2006; 21: i11-23. [CrossRef] [PubMed] [Google Scholar]
  51. Bagshaw SM, Culleton BF. Contrast-induced nephropathy: epidemiology and prevention. Minerva Cardioangiol. 2006; 54: 109-29. [PubMed] [Google Scholar]
  52. Heinrich MC, Scheer M, Heckmann M, Kuefner MA, Uder M. Iodixanol induces apoptotic and antiproliferative effects but no necrotic cell death in renal proximal tubular cells in vitro. Rofo 2009; 181: 349-54. [CrossRef] [PubMed] [Google Scholar]
  53. Yao L, Kolluru GK, Kevil CG, Zhang WW. Intravascular radiocontrast iodixanol increases permeability of proximal tubule epithelium: a possible mechanism of contrast-induced nephropathy. Vasc Endovascular Surg. 2013; 47: 632-8. [CrossRef] [PubMed] [Google Scholar]
  54. Lerch M, Keller M, Britschgi M, Kanny G, Tache V, Schmid DA, et al. Cross-reactivity patterns of T cells specific for iodinated contrast media. J Allergy Clin Immunol. 2007; 119: 1529-36. [CrossRef] [PubMed] [Google Scholar]
  55. Zager RA, Johnson AC, Hanson SY. Radiographic contrast mediainduced tubular injury: evaluation of oxidant stress and plasma membrane integrity. Kidney Int. 2003; 64: 128-39. [CrossRef] [PubMed] [Google Scholar]
  56. Yokomaku Y, Sugimoto T, Kume S, Araki S, Isshiki K, Chin-Kanasaki M, et al. Asialoerythropoietin prevents contrast-induced nephropathy. J Am Soc Nephrol. 2008; 19: 321-8. [CrossRef] [Google Scholar]
  57. Duan S, Zhou X, Liu F, Peng Y, Chen Y, Pei Y, et al. Comparative cytotoxicity of high-osmolar and low-osmolar contrast media on HKCs in vitro. J Nephrol. 2006; 19: 717-24. [PubMed] [Google Scholar]
  58. Heinrich M, Scheer M, Heckmann M, Bautz W, Uder M. Reversibility and time-dependency of contrast medium induced inhibition of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide (MTT) conversion in renal proximal tubular cells in vitro: comparison of a monomeric and a dimeric nonionic iodinated contrast medium. Invest Radiol. 2007; 42: 732-8. [CrossRef] [PubMed] [Google Scholar]
  59. Yang JS, Lu CC, Kuo SC, Hsu YM, Tsai SC, Chen SY, et al. Autophagy and its link to type II diabetes mellitus. Biomedicine. (Taipei) 2017; 7: 8. [CrossRef] [PubMed] [Google Scholar]
  60. Jensen H, Doughty RW, Grant D, Myhre O. The effects of the iodinated X-ray contrast media iodixanol, iohexol, iopromide, and ioversol on the rat kidney epithelial cell line NRK 52-E. Ren Fail. 2011; 33: 426-33. [CrossRef] [PubMed] [Google Scholar]
  61. Ko GJ, Bae SY, Hong YA, Pyo HJ, Kwon YJ. Radiocontrast-induced nephropathy is attenuated by autophagy through regulation of apoptosis and inflammation. Hum Exp Toxicol. 2016; 35: 724-36. [CrossRef] [PubMed] [Google Scholar]
  62. Kolyada AY, Liangos O, Madias NE, Jaber BL. Protective effect of erythropoietin against radiocontrast-induced renal tubular epithelial cell injury. Am J Nephrol. 2008; 28: 203-9. [CrossRef] [PubMed] [Google Scholar]
  63. He X, Yang J, Li L, Tan H, Wu Y, Ran P, et al. Atorvastatin protects against contrast-induced nephropathy via anti-apoptosis by the upregulation of Hsp27 in vivo and in vitro. Mol Med Rep. 2017; 15: 1963-72. [CrossRef] [PubMed] [Google Scholar]
  64. Sayarlioglu H, Okuyucu A, Bedir A, Salis O, Yenen E, Bekfilavioglu G, et al. Is there any role of epithelial to mesenchymal transition in the pathogenesis of contrast nephropathy? Ren Fail. 2016; 38: 1249-55. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.